Plain-English translation of NCT04900623 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a special blood test called NavDx can help doctors personalize treatment for HPV-related throat cancer. The blood test measures cancer DNA floating in your bloodstream, which may help predict how well you'll respond to treatment. Based on your test results, you may receive lower doses of radiation or chemotherapy if your cancer appears less aggressive.
Standard treatment for this type of throat cancer involves intense radiation and chemotherapy, which can cause serious side effects. Researchers hope this blood test can identify patients who might do just as well with lower, gentler doses of treatment, reducing harm while still curing the cancer.
You likely qualify if…
You likely don't qualify if…
You'll have blood drawn before treatment starts for the NavDx blood test, which the company provides free of charge. Based on your results, you'll receive either standard or lower-dose radiation therapy (lasting 5–7 weeks) with or without chemotherapy, as determined by your doctor. You'll return for follow-up visits during and after treatment, with ongoing monitoring for 5 years to track how well you're doing.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States